Related Experiment Video

Updated: May 8, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Modulation of antitumour immune responses by intratumoural Stat1 expression

Nicole L Messina1, Kellie M Banks, Eva Vidacs

  • 11] Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia [2] Deptartment of Pathology, University of Melbourne, Parkville, Victoria, Australia.

Immunology and Cell Biology
|August 21, 2013
PubMed

Insights

Tumor cell Stat1 (Signal transducer and activator of transcription 1) deficiency enhances sarcoma development. Stat1 expression shifts immune response from NK cells to CD8+ T cells, improving tumor immunosurveillance.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Signal transducer and activator of transcription 1 (Stat1) plays a crucial role in anti-viral and anti-tumor immune responses.
  • Dysregulated Stat1 function is implicated in tumor progression, highlighting the need to understand its role in immunosurveillance.

Purpose of the Study:

  • To investigate the impact of tumor cell-intrinsic Stat1 expression on the immune system's ability to detect and eliminate cancer cells (immunosurveillance).
  • To determine the specific immune cells involved in controlling tumors with varying Stat1 expression levels.

Main Methods:

  • Generated and utilized mice lacking Stat1 (Stat1 knockout) to study chemically induced sarcomas (MCA-induced).
  • Assessed tumor growth in wild-type, Stat1-deficient, and immunocompromised recipient mice.
  • Depleted specific immune cell populations (NK cells, CD4+ T cells, CD8+ T cells) to identify their roles in anti-tumor immunity.
  • Performed in vitro and in vivo analyses to elucidate the mechanisms of tumor cell killing.

Main Results:

  • Loss of Stat1 in tumor cells accelerated sarcoma development.
  • Stat1-deficient tumors were rejected more effectively by wild-type mice compared to Stat1-deficient or immunocompromised mice, indicating an immune-mediated effect.
  • Natural killer (NK) cells, through perforin-dependent mechanisms, were identified as key effectors against Stat1-deficient tumors.
  • Tumor Stat1 expression modulated the dominant immune response, favoring NK cell activity in its absence and CD8+ T cell activity in its presence.

Conclusions:

  • Tumor cell Stat1 expression is a critical determinant of the anti-tumor immune response.
  • Stat1 deficiency promotes tumor growth by shifting the immune effector balance away from CD8+ T cells towards NK cells.
  • Restoring Stat1 expression in tumors enhances immunosurveillance by promoting CD8+ T cell-mediated killing.

More Related Videos

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...